Clinical Trial Search

Primary: The Maximum Tolerated Dose of Lapatinib When Combined With Cranial Radiation in Patients With CNS Metastases From HER2-positive Breast Cancer. — 1250 milligrams

Primary: Mean Number of Adverse Events Following Each Dose — 2.5; 0.4; 0.8; 0.4 Mean number of adverse events

Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL

Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale

Primary: Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point — 7.0; 13.0; 12.6 msec — p=<0.001

Primary: Clearance (CL) — 0.278 L/h/kg

Primary: Physical Function — 62.04; 48.67 units on a scale

Primary: Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine…

Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale

Primary: Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus…

Primary: Passive Haemagglutination Inhibition Titer. — 380; 440 Titer

Primary: Investigator Defined Dose Limiting Toxicity (DLT) During First Course of Treatment, Treated Set — 6; 2; 1; 6 participants

Primary: Area Under Curve From 0 to tz (AUC0-tz) — 392; 478; 438 ng*h/mL — p=0.1009

Primary: Area Under the Curve at Steady State — 178.0 mg*hr/L

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants